Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Net Margin of 9.69% for Q1 2026, up 10313.0% year-over-year from N/an in Q1 2025, and up 92.34% quarter-over-quarter from 126.37% in Q4 2025.
Powered by 
Analysis
Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 9.69% for Q1 2026.
- In Q1 2026, Net Margin rose 10313.0% year-over-year to 9.69%; the TTM figure through Mar 2026 stood at 90.01% (up 2981.0% YoY), while the FY2025 annual figure was 124.24%, down 2407.0% from the prior year.
- Net Margin for Q1 2026 stood at 9.69%, up from 126.37% in the prior quarter.
- The five-year high for Net Margin was 64.57% in Q2 2022, with the low at 249.84% in Q3 2024.
- The 5-year median for Net Margin is 26.53% (2024), against an average of 51.06%.
- The sharpest annual moves came in 2024 and 2025: Net Margin slumped 22726 bps in 2024, then jumped 14161 bps in 2025.
- Maravai Lifesciences Holdings' Net Margin stood at 42.71% in 2022, then sank by 447 bps to 148.34% in 2023, then surged by 45 bps to 81.45% in 2024, then plunged by 55 bps to 126.37% in 2025, then surged by 92 bps to 9.69% in 2026.
- Business Quant data shows MRVI's Net Margin at 9.69% in Q1 2026, 126.37% in Q4 2025, and 108.23% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Maravai Lifesciences Holdings | 1.09 Bn | 1.02 Bn | 20.65 Mn | -42.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.05% |
| Mar 31, 2026 | -9.69% |
| Dec 31, 2025 | -126.37% |
| Sep 30, 2025 | -108.23% |
| Jun 30, 2025 | -147.34% |
| Mar 31, 2025 | -112.81% |
| Dec 31, 2024 | -81.45% |
| Sep 30, 2024 | -249.84% |
| Jun 30, 2024 | -26.53% |
| Mar 31, 2024 | -35.34% |
| Dec 31, 2023 | -148.34% |
| Sep 30, 2023 | -22.59% |
| Jun 30, 2023 | -17.33% |
| Mar 31, 2023 | -1.71% |
| Dec 31, 2022 | 42.71% |
| Sep 30, 2022 | 52.10% |
| Jun 30, 2022 | 64.57% |
| Mar 31, 2022 | 60.12% |
| Dec 31, 2021 | 55.64% |
| Sep 30, 2021 | 64.54% |